June 08, 2019 – For some time now, Tofacitinib (Xeljanz) receives intense attention in the media, with regulatory authorities, and patients and treating physicians alike because of serious concerns of increased risk of blood clots in the lungs and increased mortality in patients …

Tofacitinib (Xeljanz): Dangers of blood clots in the lungs and of death Read more »